Millennium Management’s Cartesian Therapeutics RNAC Stock Holding History

Millennium Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Buy	284,317 +119,951	+73%	+$855K	﹤0.01%	3995
2025 Q4	$1.19M	Buy	164,366 +139,009	+548%	+$1.12M	﹤0.01%	4370
2025 Q3	$259K	Buy	+25,357	New	+$285K	﹤0.01%	5416
2024 Q2	–	Sell	-33,154	Closed	-$647K	–	6431
2024 Q1	$647K	Buy	33,154 +25,961	+361%	+$550K	﹤0.01%	4633
2023 Q4	$149K	Buy	+7,193	New	+$215K	﹤0.01%	5250
2023 Q3	–	Sell	-41,210	Closed	-$1.38M	–	6496
2023 Q2	$1.38M	Sell	41,210 -21,652	-34%	-$775K	﹤0.01%	3778
2023 Q1	$2.62M	Buy	62,862 +7,765	+14%	+$365K	﹤0.01%	3176
2022 Q4	$1.87M	Sell	55,097 -106,428	-66%	-$4.53M	﹤0.01%	3630
2022 Q3	$7.95M	Buy	161,525 +118,093	+272%	+$6.49M	﹤0.01%	2433
2022 Q2	$1.71M	Sell	43,432 -17,838	-29%	-$529K	﹤0.01%	3868
2022 Q1	$2.26M	Buy	61,270 +26,244	+75%	+$1.64M	﹤0.01%	3763
2021 Q4	$3.43M	Buy	35,026 +22,883	+188%	+$2.46M	﹤0.01%	3265
2021 Q3	$1.51M	Sell	12,143 -30,022	-71%	-$3.63M	﹤0.01%	4225
2021 Q2	$5.29M	Buy	42,165 +4,787	+13%	+$570K	﹤0.01%	2684
2021 Q1	$5.07M	Buy	37,378 +16,177	+76%	+$2.01M	﹤0.01%	2552
2020 Q4	$1.93M	Sell	21,201 -32,101	-60%	-$2.78M	﹤0.01%	3268
2020 Q3	$3.97K	Sell	53,302 -4,672	-8%	-$358K	﹤0.01%	2048
2020 Q2	$4.94M	Sell	57,974 -27,861	-32%	-$2.53M	0.01%	1776
2020 Q1	$6.21M	Buy	85,835 +39,392	+85%	+$3.8M	0.01%	1172
2019 Q4	$3.32M	Buy	46,443 +37,675	+430%	+$1.82M	﹤0.01%	2247
2019 Q3	$460K	Sell	8,768 -4,819	-35%	-$256K	﹤0.01%	3314
2019 Q2	$730K	Buy	+13,587	New	+$926K	﹤0.01%	2999
2019 Q1	–	Sell	-350	Closed	-$28K	–	4278
2018 Q4	$28K	Sell	350 -3,979	-92%	-$908K	﹤0.01%	3652
2018 Q3	$2.02M	Buy	4,329 +347	+9%	+$139K	﹤0.01%	2427
2018 Q2	$1.58M	Buy	+3,982	New	+$1.41M	﹤0.01%	2555
2018 Q1	–	Sell	-9,509	Closed	-$2.8M	–	4014
2017 Q4	$2.8M	Buy	9,509 +7,405	+352%	+$3.24M	﹤0.01%	2074
2017 Q3	$1.15M	Sell	2,104 -6,784	-76%	-$3.61M	﹤0.01%	2442
2017 Q2	$5.3M	Buy	8,888 +986	+12%	+$436K	0.01%	1467
2017 Q1	$3.4M	Buy	7,902 +3,835	+94%	+$1.61M	0.01%	1681
2016 Q4	$2.09M	Buy	+4,067	New	+$2.38M	﹤0.01%	1852
2016 Q3	–	Sell	-852	Closed	-$358K	–	3551
2016 Q2	$358K	Buy	+852	New	+$358K	﹤0.01%	2653

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Millennium Management's RNAC Position: Q1 2026 in Review

Millennium Management increased its Cartesian Therapeutics (RNAC) stake by 73% in Q1 2026, buying an estimated $855K and bringing the position to 284,317 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3995.

Millennium Management first reported a position in RNAC in Q2 2016 and has held it in 31 quarters since. The position peaked at $7.95M in Q3 2022. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Millennium Management held 284,317 shares of Cartesian Therapeutics worth $1.75M as of Q1 2026.
Millennium Management bought 119,951 Cartesian Therapeutics shares in Q1 2026, an estimated $855K.
Cartesian Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3995 holding.
Millennium Management first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 31 quarters since.
Millennium Management's Cartesian Therapeutics position peaked at $7.95M in Q3 2022.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.